nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—thyroid cancer—germ cell cancer	0.613	1	CtDrD
Vandetanib—ABCC1—Dactinomycin—germ cell cancer	0.0336	0.21	CbGbCtD
Vandetanib—ABCG2—Dactinomycin—germ cell cancer	0.0225	0.141	CbGbCtD
Vandetanib—ABCC1—Vinblastine—germ cell cancer	0.021	0.132	CbGbCtD
Vandetanib—ABCC1—Etoposide—germ cell cancer	0.019	0.119	CbGbCtD
Vandetanib—ABCG2—Cisplatin—germ cell cancer	0.0129	0.0808	CbGbCtD
Vandetanib—ABCG2—Etoposide—germ cell cancer	0.0127	0.0794	CbGbCtD
Vandetanib—ABCC1—Methotrexate—germ cell cancer	0.0125	0.0784	CbGbCtD
Vandetanib—ABCG2—Methotrexate—germ cell cancer	0.00838	0.0524	CbGbCtD
Vandetanib—ALB—Methotrexate—germ cell cancer	0.00578	0.0361	CbGbCtD
Vandetanib—CYP3A4—Ifosfamide—germ cell cancer	0.00573	0.0359	CbGbCtD
Vandetanib—CYP3A4—Vinblastine—germ cell cancer	0.00304	0.019	CbGbCtD
Vandetanib—CYP3A4—Etoposide—germ cell cancer	0.00274	0.0171	CbGbCtD
Vandetanib—ERBB3—Podofilox—Etoposide—germ cell cancer	0.00097	0.566	CbGdCrCtD
Vandetanib—PLK4—Teniposide—Etoposide—germ cell cancer	0.000743	0.434	CbGdCrCtD
Vandetanib—Alopecia—Bleomycin—germ cell cancer	0.000162	0.00246	CcSEcCtD
Vandetanib—Erythema multiforme—Dactinomycin—germ cell cancer	0.000162	0.00245	CcSEcCtD
Vandetanib—Bradycardia—Ifosfamide—germ cell cancer	0.00016	0.00242	CcSEcCtD
Vandetanib—Alanine aminotransferase increased—Etoposide—germ cell cancer	0.000158	0.00239	CcSEcCtD
Vandetanib—Haemoglobin—Ifosfamide—germ cell cancer	0.000158	0.00239	CcSEcCtD
Vandetanib—Haemorrhage—Ifosfamide—germ cell cancer	0.000157	0.00237	CcSEcCtD
Vandetanib—Urinary tract disorder—Ifosfamide—germ cell cancer	0.000155	0.00235	CcSEcCtD
Vandetanib—Dysphagia—Etoposide—germ cell cancer	0.000155	0.00234	CcSEcCtD
Vandetanib—Urethral disorder—Ifosfamide—germ cell cancer	0.000154	0.00233	CcSEcCtD
Vandetanib—Bronchospasm—Etoposide—germ cell cancer	0.000152	0.00231	CcSEcCtD
Vandetanib—Alopecia—Dactinomycin—germ cell cancer	0.000151	0.00229	CcSEcCtD
Vandetanib—Thrombocytopenia—Vinblastine—germ cell cancer	0.000151	0.00229	CcSEcCtD
Vandetanib—Visual impairment—Ifosfamide—germ cell cancer	0.000151	0.00229	CcSEcCtD
Vandetanib—Respiratory failure—Methotrexate—germ cell cancer	0.00015	0.00228	CcSEcCtD
Vandetanib—Erythema multiforme—Ifosfamide—germ cell cancer	0.000148	0.00225	CcSEcCtD
Vandetanib—Renal failure—Cisplatin—germ cell cancer	0.000148	0.00224	CcSEcCtD
Vandetanib—Stomatitis—Cisplatin—germ cell cancer	0.000147	0.00222	CcSEcCtD
Vandetanib—Eye disorder—Ifosfamide—germ cell cancer	0.000147	0.00222	CcSEcCtD
Vandetanib—Conjunctivitis—Cisplatin—germ cell cancer	0.000146	0.00222	CcSEcCtD
Vandetanib—Cardiac disorder—Ifosfamide—germ cell cancer	0.000146	0.0022	CcSEcCtD
Vandetanib—Neutropenia—Etoposide—germ cell cancer	0.000145	0.00219	CcSEcCtD
Vandetanib—Cystitis noninfective—Methotrexate—germ cell cancer	0.000144	0.00219	CcSEcCtD
Vandetanib—Depressed level of consciousness—Methotrexate—germ cell cancer	0.000143	0.00216	CcSEcCtD
Vandetanib—Cystitis—Methotrexate—germ cell cancer	0.000143	0.00216	CcSEcCtD
Vandetanib—Hepatobiliary disease—Cisplatin—germ cell cancer	0.000142	0.00216	CcSEcCtD
Vandetanib—Angiopathy—Ifosfamide—germ cell cancer	0.000142	0.00215	CcSEcCtD
Vandetanib—Mediastinal disorder—Ifosfamide—germ cell cancer	0.000141	0.00214	CcSEcCtD
Vandetanib—Arrhythmia—Ifosfamide—germ cell cancer	0.00014	0.00212	CcSEcCtD
Vandetanib—Cough—Bleomycin—germ cell cancer	0.000139	0.00211	CcSEcCtD
Vandetanib—Pneumonia—Etoposide—germ cell cancer	0.000139	0.0021	CcSEcCtD
Vandetanib—Paraesthesia—Vinblastine—germ cell cancer	0.000139	0.0021	CcSEcCtD
Vandetanib—Alopecia—Ifosfamide—germ cell cancer	0.000139	0.0021	CcSEcCtD
Vandetanib—Infestation NOS—Etoposide—germ cell cancer	0.000138	0.00209	CcSEcCtD
Vandetanib—Infestation—Etoposide—germ cell cancer	0.000138	0.00209	CcSEcCtD
Vandetanib—Bradycardia—Cisplatin—germ cell cancer	0.000138	0.00208	CcSEcCtD
Vandetanib—Mental disorder—Ifosfamide—germ cell cancer	0.000137	0.00208	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Etoposide—germ cell cancer	0.000137	0.00207	CcSEcCtD
Vandetanib—Malnutrition—Ifosfamide—germ cell cancer	0.000137	0.00207	CcSEcCtD
Vandetanib—Chest pain—Bleomycin—germ cell cancer	0.000136	0.00206	CcSEcCtD
Vandetanib—Renal failure—Etoposide—germ cell cancer	0.000136	0.00205	CcSEcCtD
Vandetanib—Stomatitis—Etoposide—germ cell cancer	0.000135	0.00204	CcSEcCtD
Vandetanib—PLK4—lymph node—germ cell cancer	0.000134	0.00166	CbGeAlD
Vandetanib—Decreased appetite—Vinblastine—germ cell cancer	0.000134	0.00203	CcSEcCtD
Vandetanib—ERBB3—endocrine gland—germ cell cancer	0.000134	0.00166	CbGeAlD
Vandetanib—STK35—cerebellum—germ cell cancer	0.000134	0.00165	CbGeAlD
Vandetanib—FGR—female gonad—germ cell cancer	0.000134	0.00165	CbGeAlD
Vandetanib—LCK—female gonad—germ cell cancer	0.000134	0.00165	CbGeAlD
Vandetanib—FYN—adrenal gland—germ cell cancer	0.000134	0.00165	CbGeAlD
Vandetanib—RIPK2—testis—germ cell cancer	0.000134	0.00165	CbGeAlD
Vandetanib—Neoplasm—Methotrexate—germ cell cancer	0.000134	0.00202	CcSEcCtD
Vandetanib—Bladder pain—Methotrexate—germ cell cancer	0.000134	0.00202	CcSEcCtD
Vandetanib—Urinary tract disorder—Cisplatin—germ cell cancer	0.000134	0.00202	CcSEcCtD
Vandetanib—VEGFA—testis—germ cell cancer	0.000133	0.00165	CbGeAlD
Vandetanib—AXL—female gonad—germ cell cancer	0.000133	0.00165	CbGeAlD
Vandetanib—SRC—gonad—germ cell cancer	0.000133	0.00165	CbGeAlD
Vandetanib—SLK—bone marrow—germ cell cancer	0.000133	0.00164	CbGeAlD
Vandetanib—Urethral disorder—Cisplatin—germ cell cancer	0.000133	0.00201	CcSEcCtD
Vandetanib—SLK—spinal cord—germ cell cancer	0.000132	0.00164	CbGeAlD
Vandetanib—ERBB3—head—germ cell cancer	0.000132	0.00164	CbGeAlD
Vandetanib—Constipation—Vinblastine—germ cell cancer	0.000132	0.002	CcSEcCtD
Vandetanib—Pain—Vinblastine—germ cell cancer	0.000132	0.002	CcSEcCtD
Vandetanib—FYN—midbrain—germ cell cancer	0.000132	0.00163	CbGeAlD
Vandetanib—TEK—adrenal gland—germ cell cancer	0.000131	0.00161	CbGeAlD
Vandetanib—MAP4K5—adrenal gland—germ cell cancer	0.000131	0.00161	CbGeAlD
Vandetanib—EPHA5—brain—germ cell cancer	0.000131	0.00161	CbGeAlD
Vandetanib—TYRO3—brain—germ cell cancer	0.000131	0.00161	CbGeAlD
Vandetanib—Hepatobiliary disease—Etoposide—germ cell cancer	0.000131	0.00198	CcSEcCtD
Vandetanib—IRAK4—testis—germ cell cancer	0.000131	0.00161	CbGeAlD
Vandetanib—ABL2—cerebellum—germ cell cancer	0.00013	0.00161	CbGeAlD
Vandetanib—Oedema—Bleomycin—germ cell cancer	0.00013	0.00197	CcSEcCtD
Vandetanib—YES1—medulla oblongata—germ cell cancer	0.00013	0.00161	CbGeAlD
Vandetanib—Visual impairment—Cisplatin—germ cell cancer	0.00013	0.00197	CcSEcCtD
Vandetanib—LYN—brain—germ cell cancer	0.00013	0.0016	CbGeAlD
Vandetanib—Infection—Bleomycin—germ cell cancer	0.00013	0.00196	CcSEcCtD
Vandetanib—FYN—bone marrow—germ cell cancer	0.000129	0.0016	CbGeAlD
Vandetanib—TEK—midbrain—germ cell cancer	0.000129	0.00159	CbGeAlD
Vandetanib—MAP4K5—midbrain—germ cell cancer	0.000129	0.00159	CbGeAlD
Vandetanib—FYN—spinal cord—germ cell cancer	0.000129	0.00159	CbGeAlD
Vandetanib—Vision blurred—Ifosfamide—germ cell cancer	0.000129	0.00195	CcSEcCtD
Vandetanib—SLK—female gonad—germ cell cancer	0.000128	0.00158	CbGeAlD
Vandetanib—Sepsis—Methotrexate—germ cell cancer	0.000128	0.00194	CcSEcCtD
Vandetanib—ERBB3—testis—germ cell cancer	0.000128	0.00158	CbGeAlD
Vandetanib—BMPR1B—brain—germ cell cancer	0.000128	0.00158	CbGeAlD
Vandetanib—MAP3K19—brain—germ cell cancer	0.000128	0.00158	CbGeAlD
Vandetanib—Thrombocytopenia—Bleomycin—germ cell cancer	0.000128	0.00193	CcSEcCtD
Vandetanib—ABL1—brainstem—germ cell cancer	0.000128	0.00158	CbGeAlD
Vandetanib—EGFR—cerebellum—germ cell cancer	0.000127	0.00157	CbGeAlD
Vandetanib—PDGFRB—telencephalon—germ cell cancer	0.000127	0.00157	CbGeAlD
Vandetanib—MAP4K5—bone marrow—germ cell cancer	0.000126	0.00156	CbGeAlD
Vandetanib—Eye disorder—Cisplatin—germ cell cancer	0.000126	0.00191	CcSEcCtD
Vandetanib—Gastrointestinal pain—Vinblastine—germ cell cancer	0.000126	0.00191	CcSEcCtD
Vandetanib—MKNK1—endocrine gland—germ cell cancer	0.000126	0.00156	CbGeAlD
Vandetanib—MAP4K5—spinal cord—germ cell cancer	0.000126	0.00155	CbGeAlD
Vandetanib—TEK—spinal cord—germ cell cancer	0.000126	0.00155	CbGeAlD
Vandetanib—Cardiac disorder—Cisplatin—germ cell cancer	0.000126	0.0019	CcSEcCtD
Vandetanib—EPHB6—adrenal gland—germ cell cancer	0.000125	0.00154	CbGeAlD
Vandetanib—FYN—female gonad—germ cell cancer	0.000125	0.00154	CbGeAlD
Vandetanib—FGR—endocrine gland—germ cell cancer	0.000124	0.00154	CbGeAlD
Vandetanib—RET—endocrine gland—germ cell cancer	0.000124	0.00154	CbGeAlD
Vandetanib—MKNK1—head—germ cell cancer	0.000124	0.00154	CbGeAlD
Vandetanib—ABL1—eye—germ cell cancer	0.000124	0.00153	CbGeAlD
Vandetanib—AXL—endocrine gland—germ cell cancer	0.000124	0.00153	CbGeAlD
Vandetanib—BMPR1B—lymph node—germ cell cancer	0.000124	0.00153	CbGeAlD
Vandetanib—RIPK2—cerebellum—germ cell cancer	0.000123	0.00152	CbGeAlD
Vandetanib—EPHB6—midbrain—germ cell cancer	0.000123	0.00152	CbGeAlD
Vandetanib—ABL1—retina—germ cell cancer	0.000123	0.00152	CbGeAlD
Vandetanib—VEGFA—cerebellum—germ cell cancer	0.000123	0.00152	CbGeAlD
Vandetanib—RET—head—germ cell cancer	0.000123	0.00152	CbGeAlD
Vandetanib—FGR—head—germ cell cancer	0.000123	0.00152	CbGeAlD
Vandetanib—Urinary tract disorder—Etoposide—germ cell cancer	0.000122	0.00185	CcSEcCtD
Vandetanib—AXL—head—germ cell cancer	0.000122	0.00151	CbGeAlD
Vandetanib—Abdominal pain—Vinblastine—germ cell cancer	0.000122	0.00185	CcSEcCtD
Vandetanib—Mediastinal disorder—Cisplatin—germ cell cancer	0.000122	0.00185	CcSEcCtD
Vandetanib—TEK—female gonad—germ cell cancer	0.000122	0.00151	CbGeAlD
Vandetanib—MAP4K5—female gonad—germ cell cancer	0.000122	0.00151	CbGeAlD
Vandetanib—KDR—uterus—germ cell cancer	0.000122	0.0015	CbGeAlD
Vandetanib—Oedema—Dactinomycin—germ cell cancer	0.000122	0.00184	CcSEcCtD
Vandetanib—Urethral disorder—Etoposide—germ cell cancer	0.000121	0.00184	CcSEcCtD
Vandetanib—PDGFRB—skin of body—germ cell cancer	0.000121	0.0015	CbGeAlD
Vandetanib—Infection—Dactinomycin—germ cell cancer	0.000121	0.00183	CcSEcCtD
Vandetanib—Arrhythmia—Cisplatin—germ cell cancer	0.000121	0.00183	CcSEcCtD
Vandetanib—YES1—adrenal gland—germ cell cancer	0.000121	0.00149	CbGeAlD
Vandetanib—IRAK4—cerebellum—germ cell cancer	0.000121	0.00149	CbGeAlD
Vandetanib—PDGFRB—decidua—germ cell cancer	0.00012	0.00149	CbGeAlD
Vandetanib—EPHB6—spinal cord—germ cell cancer	0.00012	0.00149	CbGeAlD
Vandetanib—FMO3—endocrine gland—germ cell cancer	0.00012	0.00148	CbGeAlD
Vandetanib—MKNK1—testis—germ cell cancer	0.00012	0.00148	CbGeAlD
Vandetanib—STK10—adrenal gland—germ cell cancer	0.00012	0.00148	CbGeAlD
Vandetanib—MAP2K5—pituitary gland—germ cell cancer	0.00012	0.00148	CbGeAlD
Vandetanib—KDR—pituitary gland—germ cell cancer	0.00012	0.00148	CbGeAlD
Vandetanib—Alopecia—Cisplatin—germ cell cancer	0.00012	0.00181	CcSEcCtD
Vandetanib—Cough—Ifosfamide—germ cell cancer	0.000119	0.0018	CcSEcCtD
Vandetanib—YES1—midbrain—germ cell cancer	0.000119	0.00147	CbGeAlD
Vandetanib—Thrombocytopenia—Dactinomycin—germ cell cancer	0.000119	0.0018	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Bleomycin—germ cell cancer	0.000119	0.0018	CcSEcCtD
Vandetanib—FGR—testis—germ cell cancer	0.000119	0.00147	CbGeAlD
Vandetanib—LCK—testis—germ cell cancer	0.000119	0.00147	CbGeAlD
Vandetanib—RET—testis—germ cell cancer	0.000119	0.00147	CbGeAlD
Vandetanib—FMO3—head—germ cell cancer	0.000119	0.00147	CbGeAlD
Vandetanib—Convulsion—Ifosfamide—germ cell cancer	0.000118	0.00179	CcSEcCtD
Vandetanib—AXL—testis—germ cell cancer	0.000118	0.00146	CbGeAlD
Vandetanib—ERBB3—cerebellum—germ cell cancer	0.000118	0.00146	CbGeAlD
Vandetanib—Hypertension—Ifosfamide—germ cell cancer	0.000118	0.00178	CcSEcCtD
Vandetanib—Malnutrition—Cisplatin—germ cell cancer	0.000118	0.00178	CcSEcCtD
Vandetanib—Erythema multiforme—Etoposide—germ cell cancer	0.000117	0.00177	CcSEcCtD
Vandetanib—Paraesthesia—Bleomycin—germ cell cancer	0.000117	0.00177	CcSEcCtD
Vandetanib—YES1—bone marrow—germ cell cancer	0.000117	0.00144	CbGeAlD
Vandetanib—EPHB6—female gonad—germ cell cancer	0.000116	0.00144	CbGeAlD
Vandetanib—Dyspnoea—Bleomycin—germ cell cancer	0.000116	0.00176	CcSEcCtD
Vandetanib—Chest pain—Ifosfamide—germ cell cancer	0.000116	0.00176	CcSEcCtD
Vandetanib—Arthralgia—Ifosfamide—germ cell cancer	0.000116	0.00176	CcSEcCtD
Vandetanib—YES1—spinal cord—germ cell cancer	0.000116	0.00144	CbGeAlD
Vandetanib—SRC—adrenal gland—germ cell cancer	0.000116	0.00143	CbGeAlD
Vandetanib—FYN—endocrine gland—germ cell cancer	0.000116	0.00143	CbGeAlD
Vandetanib—Eye disorder—Etoposide—germ cell cancer	0.000116	0.00175	CcSEcCtD
Vandetanib—STK10—bone marrow—germ cell cancer	0.000116	0.00143	CbGeAlD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—germ cell cancer	0.000115	0.00175	CcSEcCtD
Vandetanib—KDR—medulla oblongata—germ cell cancer	0.000115	0.00143	CbGeAlD
Vandetanib—MAP2K5—medulla oblongata—germ cell cancer	0.000115	0.00143	CbGeAlD
Vandetanib—Cardiac disorder—Etoposide—germ cell cancer	0.000115	0.00174	CcSEcCtD
Vandetanib—FMO3—testis—germ cell cancer	0.000115	0.00142	CbGeAlD
Vandetanib—FYN—head—germ cell cancer	0.000114	0.00141	CbGeAlD
Vandetanib—SLK—testis—germ cell cancer	0.000114	0.00141	CbGeAlD
Vandetanib—Decreased appetite—Bleomycin—germ cell cancer	0.000113	0.00172	CcSEcCtD
Vandetanib—MAP4K5—endocrine gland—germ cell cancer	0.000113	0.0014	CbGeAlD
Vandetanib—TEK—endocrine gland—germ cell cancer	0.000113	0.0014	CbGeAlD
Vandetanib—ABL1—telencephalon—germ cell cancer	0.000113	0.0014	CbGeAlD
Vandetanib—Muscle spasms—Cisplatin—germ cell cancer	0.000113	0.00171	CcSEcCtD
Vandetanib—YES1—female gonad—germ cell cancer	0.000113	0.00139	CbGeAlD
Vandetanib—Angiopathy—Etoposide—germ cell cancer	0.000112	0.0017	CcSEcCtD
Vandetanib—TEK—head—germ cell cancer	0.000112	0.00138	CbGeAlD
Vandetanib—MAP4K5—head—germ cell cancer	0.000112	0.00138	CbGeAlD
Vandetanib—SRC—spinal cord—germ cell cancer	0.000112	0.00138	CbGeAlD
Vandetanib—Mediastinal disorder—Etoposide—germ cell cancer	0.000112	0.00169	CcSEcCtD
Vandetanib—STK10—female gonad—germ cell cancer	0.000112	0.00138	CbGeAlD
Vandetanib—Pain—Bleomycin—germ cell cancer	0.000112	0.00169	CcSEcCtD
Vandetanib—Oedema—Ifosfamide—germ cell cancer	0.000111	0.00169	CcSEcCtD
Vandetanib—Vision blurred—Cisplatin—germ cell cancer	0.000111	0.00168	CcSEcCtD
Vandetanib—MKNK1—cerebellum—germ cell cancer	0.000111	0.00137	CbGeAlD
Vandetanib—Musculoskeletal discomfort—Dactinomycin—germ cell cancer	0.000111	0.00168	CcSEcCtD
Vandetanib—Asthenia—Vinblastine—germ cell cancer	0.000111	0.00168	CcSEcCtD
Vandetanib—Infection—Ifosfamide—germ cell cancer	0.000111	0.00168	CcSEcCtD
Vandetanib—FYN—testis—germ cell cancer	0.000111	0.00137	CbGeAlD
Vandetanib—Tremor—Cisplatin—germ cell cancer	0.00011	0.00167	CcSEcCtD
Vandetanib—RET—cerebellum—germ cell cancer	0.00011	0.00135	CbGeAlD
Vandetanib—Alopecia—Etoposide—germ cell cancer	0.000109	0.00166	CcSEcCtD
Vandetanib—Lethargy—Methotrexate—germ cell cancer	0.000109	0.00166	CcSEcCtD
Vandetanib—Nervous system disorder—Ifosfamide—germ cell cancer	0.000109	0.00165	CcSEcCtD
Vandetanib—AXL—cerebellum—germ cell cancer	0.000109	0.00135	CbGeAlD
Vandetanib—Thrombocytopenia—Ifosfamide—germ cell cancer	0.000109	0.00165	CcSEcCtD
Vandetanib—STK35—brain—germ cell cancer	0.000109	0.00134	CbGeAlD
Vandetanib—SRC—female gonad—germ cell cancer	0.000108	0.00134	CbGeAlD
Vandetanib—Skin disorder—Ifosfamide—germ cell cancer	0.000108	0.00164	CcSEcCtD
Vandetanib—ABL1—skin of body—germ cell cancer	0.000108	0.00134	CbGeAlD
Vandetanib—TEK—testis—germ cell cancer	0.000108	0.00134	CbGeAlD
Vandetanib—MAP4K5—testis—germ cell cancer	0.000108	0.00134	CbGeAlD
Vandetanib—ABL1—decidua—germ cell cancer	0.000107	0.00133	CbGeAlD
Vandetanib—FLT3—lymph node—germ cell cancer	0.000107	0.00132	CbGeAlD
Vandetanib—EPHB6—head—germ cell cancer	0.000107	0.00132	CbGeAlD
Vandetanib—MAP2K5—adrenal gland—germ cell cancer	0.000107	0.00132	CbGeAlD
Vandetanib—KDR—adrenal gland—germ cell cancer	0.000107	0.00132	CbGeAlD
Vandetanib—PDGFRB—gonad—germ cell cancer	0.000106	0.00131	CbGeAlD
Vandetanib—ABL2—brain—germ cell cancer	0.000106	0.00131	CbGeAlD
Vandetanib—Decreased appetite—Dactinomycin—germ cell cancer	0.000106	0.0016	CcSEcCtD
Vandetanib—Diarrhoea—Vinblastine—germ cell cancer	0.000106	0.0016	CcSEcCtD
Vandetanib—Dysgeusia—Etoposide—germ cell cancer	0.000106	0.0016	CcSEcCtD
Vandetanib—KDR—midbrain—germ cell cancer	0.000105	0.0013	CbGeAlD
Vandetanib—MAP2K5—midbrain—germ cell cancer	0.000105	0.0013	CbGeAlD
Vandetanib—PDGFRB—uterus—germ cell cancer	0.000105	0.0013	CbGeAlD
Vandetanib—STK35—lymph node—germ cell cancer	0.000105	0.0013	CbGeAlD
Vandetanib—SLK—cerebellum—germ cell cancer	0.000105	0.0013	CbGeAlD
Vandetanib—Fatigue—Dactinomycin—germ cell cancer	0.000105	0.00159	CcSEcCtD
Vandetanib—YES1—endocrine gland—germ cell cancer	0.000105	0.00129	CbGeAlD
Vandetanib—Pain—Dactinomycin—germ cell cancer	0.000104	0.00157	CcSEcCtD
Vandetanib—STK10—endocrine gland—germ cell cancer	0.000104	0.00128	CbGeAlD
Vandetanib—Muscle spasms—Etoposide—germ cell cancer	0.000104	0.00157	CcSEcCtD
Vandetanib—PDGFRB—pituitary gland—germ cell cancer	0.000103	0.00128	CbGeAlD
Vandetanib—EGFR—brain—germ cell cancer	0.000103	0.00128	CbGeAlD
Vandetanib—KDR—bone marrow—germ cell cancer	0.000103	0.00128	CbGeAlD
Vandetanib—YES1—head—germ cell cancer	0.000103	0.00128	CbGeAlD
Vandetanib—EPHB6—testis—germ cell cancer	0.000103	0.00128	CbGeAlD
Vandetanib—Body temperature increased—Bleomycin—germ cell cancer	0.000103	0.00156	CcSEcCtD
Vandetanib—KDR—spinal cord—germ cell cancer	0.000103	0.00127	CbGeAlD
Vandetanib—MAP2K5—spinal cord—germ cell cancer	0.000103	0.00127	CbGeAlD
Vandetanib—ABL2—lymph node—germ cell cancer	0.000102	0.00126	CbGeAlD
Vandetanib—STK10—head—germ cell cancer	0.000102	0.00126	CbGeAlD
Vandetanib—FYN—cerebellum—germ cell cancer	0.000102	0.00126	CbGeAlD
Vandetanib—Dizziness—Vinblastine—germ cell cancer	0.000102	0.00155	CcSEcCtD
Vandetanib—Convulsion—Cisplatin—germ cell cancer	0.000102	0.00154	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Ifosfamide—germ cell cancer	0.000102	0.00154	CcSEcCtD
Vandetanib—FLT4—brain—germ cell cancer	0.000101	0.00125	CbGeAlD
Vandetanib—SRC—endocrine gland—germ cell cancer	0.000101	0.00124	CbGeAlD
Vandetanib—RIPK2—brain—germ cell cancer	0.0001	0.00124	CbGeAlD
Vandetanib—Paraesthesia—Ifosfamide—germ cell cancer	0.0001	0.00152	CcSEcCtD
Vandetanib—VEGFA—brain—germ cell cancer	0.0001	0.00124	CbGeAlD
Vandetanib—EGFR—lymph node—germ cell cancer	9.99e-05	0.00123	CbGeAlD
Vandetanib—Anxiety—Cisplatin—germ cell cancer	9.99e-05	0.00151	CcSEcCtD
Vandetanib—PDGFRB—medulla oblongata—germ cell cancer	9.99e-05	0.00123	CbGeAlD
Vandetanib—TEK—cerebellum—germ cell cancer	9.98e-05	0.00123	CbGeAlD
Vandetanib—MAP4K5—cerebellum—germ cell cancer	9.98e-05	0.00123	CbGeAlD
Vandetanib—YES1—testis—germ cell cancer	9.98e-05	0.00123	CbGeAlD
Vandetanib—MAP2K5—female gonad—germ cell cancer	9.96e-05	0.00123	CbGeAlD
Vandetanib—KDR—female gonad—germ cell cancer	9.96e-05	0.00123	CbGeAlD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—germ cell cancer	9.95e-05	0.00151	CcSEcCtD
Vandetanib—Gastrointestinal pain—Dactinomycin—germ cell cancer	9.95e-05	0.00151	CcSEcCtD
Vandetanib—FMO1—brain—germ cell cancer	9.95e-05	0.00123	CbGeAlD
Vandetanib—SRC—head—germ cell cancer	9.94e-05	0.00123	CbGeAlD
Vandetanib—Dyspnoea—Ifosfamide—germ cell cancer	9.94e-05	0.0015	CcSEcCtD
Vandetanib—STK10—testis—germ cell cancer	9.89e-05	0.00122	CbGeAlD
Vandetanib—Vomiting—Vinblastine—germ cell cancer	9.82e-05	0.00149	CcSEcCtD
Vandetanib—IRAK4—brain—germ cell cancer	9.79e-05	0.00121	CbGeAlD
Vandetanib—FLT4—lymph node—germ cell cancer	9.74e-05	0.0012	CbGeAlD
Vandetanib—Decreased appetite—Ifosfamide—germ cell cancer	9.69e-05	0.00147	CcSEcCtD
Vandetanib—RIPK2—lymph node—germ cell cancer	9.69e-05	0.0012	CbGeAlD
Vandetanib—Headache—Vinblastine—germ cell cancer	9.67e-05	0.00146	CcSEcCtD
Vandetanib—VEGFA—lymph node—germ cell cancer	9.66e-05	0.00119	CbGeAlD
Vandetanib—Gastrointestinal disorder—Ifosfamide—germ cell cancer	9.62e-05	0.00146	CcSEcCtD
Vandetanib—Abdominal pain—Dactinomycin—germ cell cancer	9.61e-05	0.00146	CcSEcCtD
Vandetanib—Body temperature increased—Dactinomycin—germ cell cancer	9.61e-05	0.00146	CcSEcCtD
Vandetanib—FMO1—lymph node—germ cell cancer	9.61e-05	0.00119	CbGeAlD
Vandetanib—Fatigue—Ifosfamide—germ cell cancer	9.61e-05	0.00145	CcSEcCtD
Vandetanib—Oedema—Cisplatin—germ cell cancer	9.61e-05	0.00145	CcSEcCtD
Vandetanib—SRC—testis—germ cell cancer	9.6e-05	0.00119	CbGeAlD
Vandetanib—ERBB3—brain—germ cell cancer	9.6e-05	0.00119	CbGeAlD
Vandetanib—Infection—Cisplatin—germ cell cancer	9.55e-05	0.00145	CcSEcCtD
Vandetanib—EPHB6—cerebellum—germ cell cancer	9.54e-05	0.00118	CbGeAlD
Vandetanib—Constipation—Ifosfamide—germ cell cancer	9.53e-05	0.00144	CcSEcCtD
Vandetanib—Pain—Ifosfamide—germ cell cancer	9.53e-05	0.00144	CcSEcCtD
Vandetanib—Loss of consciousness—Etoposide—germ cell cancer	9.48e-05	0.00144	CcSEcCtD
Vandetanib—IRAK4—lymph node—germ cell cancer	9.46e-05	0.00117	CbGeAlD
Vandetanib—ABL1—gonad—germ cell cancer	9.45e-05	0.00117	CbGeAlD
Vandetanib—Nervous system disorder—Cisplatin—germ cell cancer	9.42e-05	0.00143	CcSEcCtD
Vandetanib—Cough—Etoposide—germ cell cancer	9.41e-05	0.00142	CcSEcCtD
Vandetanib—Thrombocytopenia—Cisplatin—germ cell cancer	9.41e-05	0.00142	CcSEcCtD
Vandetanib—ABL1—uterus—germ cell cancer	9.39e-05	0.00116	CbGeAlD
Vandetanib—Asthenia—Bleomycin—germ cell cancer	9.36e-05	0.00142	CcSEcCtD
Vandetanib—Convulsion—Etoposide—germ cell cancer	9.35e-05	0.00141	CcSEcCtD
Vandetanib—Skin disorder—Cisplatin—germ cell cancer	9.33e-05	0.00141	CcSEcCtD
Vandetanib—Hypertension—Etoposide—germ cell cancer	9.31e-05	0.00141	CcSEcCtD
Vandetanib—ERBB3—lymph node—germ cell cancer	9.27e-05	0.00115	CbGeAlD
Vandetanib—KDR—endocrine gland—germ cell cancer	9.26e-05	0.00114	CbGeAlD
Vandetanib—MAP2K5—endocrine gland—germ cell cancer	9.26e-05	0.00114	CbGeAlD
Vandetanib—PDGFRB—adrenal gland—germ cell cancer	9.24e-05	0.00114	CbGeAlD
Vandetanib—Pruritus—Bleomycin—germ cell cancer	9.23e-05	0.0014	CcSEcCtD
Vandetanib—ABL1—pituitary gland—germ cell cancer	9.22e-05	0.00114	CbGeAlD
Vandetanib—YES1—cerebellum—germ cell cancer	9.22e-05	0.00114	CbGeAlD
Vandetanib—Chest pain—Etoposide—germ cell cancer	9.18e-05	0.00139	CcSEcCtD
Vandetanib—Nausea—Vinblastine—germ cell cancer	9.17e-05	0.00139	CcSEcCtD
Vandetanib—MAP2K5—head—germ cell cancer	9.14e-05	0.00113	CbGeAlD
Vandetanib—KDR—head—germ cell cancer	9.14e-05	0.00113	CbGeAlD
Vandetanib—STK10—cerebellum—germ cell cancer	9.13e-05	0.00113	CbGeAlD
Vandetanib—PDGFRB—midbrain—germ cell cancer	9.13e-05	0.00113	CbGeAlD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—germ cell cancer	9.12e-05	0.00138	CcSEcCtD
Vandetanib—Gastrointestinal pain—Ifosfamide—germ cell cancer	9.11e-05	0.00138	CcSEcCtD
Vandetanib—ABCG2—trigeminal ganglion—germ cell cancer	9.1e-05	0.00112	CbGeAlD
Vandetanib—Pancreatitis—Methotrexate—germ cell cancer	9.09e-05	0.00138	CcSEcCtD
Vandetanib—MKNK1—brain—germ cell cancer	9.01e-05	0.00111	CbGeAlD
Vandetanib—PDGFRB—bone marrow—germ cell cancer	8.94e-05	0.0011	CbGeAlD
Vandetanib—PDGFRB—spinal cord—germ cell cancer	8.9e-05	0.0011	CbGeAlD
Vandetanib—ABL1—medulla oblongata—germ cell cancer	8.9e-05	0.0011	CbGeAlD
Vandetanib—FGR—brain—germ cell cancer	8.9e-05	0.0011	CbGeAlD
Vandetanib—RET—brain—germ cell cancer	8.9e-05	0.0011	CbGeAlD
Vandetanib—SRC—cerebellum—germ cell cancer	8.87e-05	0.0011	CbGeAlD
Vandetanib—AXL—brain—germ cell cancer	8.86e-05	0.0011	CbGeAlD
Vandetanib—MAP2K5—testis—germ cell cancer	8.83e-05	0.00109	CbGeAlD
Vandetanib—KDR—testis—germ cell cancer	8.83e-05	0.00109	CbGeAlD
Vandetanib—Body temperature increased—Ifosfamide—germ cell cancer	8.81e-05	0.00133	CcSEcCtD
Vandetanib—Abdominal pain—Ifosfamide—germ cell cancer	8.81e-05	0.00133	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Cisplatin—germ cell cancer	8.75e-05	0.00133	CcSEcCtD
Vandetanib—Infection—Etoposide—germ cell cancer	8.75e-05	0.00132	CcSEcCtD
Vandetanib—Asthenia—Dactinomycin—germ cell cancer	8.73e-05	0.00132	CcSEcCtD
Vandetanib—MKNK1—lymph node—germ cell cancer	8.71e-05	0.00108	CbGeAlD
Vandetanib—Neutropenia—Methotrexate—germ cell cancer	8.67e-05	0.00131	CcSEcCtD
Vandetanib—Dysuria—Methotrexate—germ cell cancer	8.67e-05	0.00131	CcSEcCtD
Vandetanib—ABCC1—telencephalon—germ cell cancer	8.63e-05	0.00107	CbGeAlD
Vandetanib—Paraesthesia—Cisplatin—germ cell cancer	8.63e-05	0.00131	CcSEcCtD
Vandetanib—PDGFRB—female gonad—germ cell cancer	8.62e-05	0.00106	CbGeAlD
Vandetanib—Thrombocytopenia—Etoposide—germ cell cancer	8.62e-05	0.0013	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Methotrexate—germ cell cancer	8.62e-05	0.0013	CcSEcCtD
Vandetanib—LCK—lymph node—germ cell cancer	8.6e-05	0.00106	CbGeAlD
Vandetanib—RET—lymph node—germ cell cancer	8.6e-05	0.00106	CbGeAlD
Vandetanib—FGR—lymph node—germ cell cancer	8.6e-05	0.00106	CbGeAlD
Vandetanib—FMO3—brain—germ cell cancer	8.6e-05	0.00106	CbGeAlD
Vandetanib—Dyspnoea—Cisplatin—germ cell cancer	8.57e-05	0.0013	CcSEcCtD
Vandetanib—AXL—lymph node—germ cell cancer	8.57e-05	0.00106	CbGeAlD
Vandetanib—Skin disorder—Etoposide—germ cell cancer	8.55e-05	0.00129	CcSEcCtD
Vandetanib—SLK—brain—germ cell cancer	8.53e-05	0.00105	CbGeAlD
Vandetanib—Photosensitivity reaction—Methotrexate—germ cell cancer	8.46e-05	0.00128	CcSEcCtD
Vandetanib—ORM1—bone marrow—germ cell cancer	8.39e-05	0.00104	CbGeAlD
Vandetanib—ORM1—spinal cord—germ cell cancer	8.35e-05	0.00103	CbGeAlD
Vandetanib—Decreased appetite—Cisplatin—germ cell cancer	8.35e-05	0.00126	CcSEcCtD
Vandetanib—Diarrhoea—Dactinomycin—germ cell cancer	8.32e-05	0.00126	CcSEcCtD
Vandetanib—Pneumonia—Methotrexate—germ cell cancer	8.32e-05	0.00126	CcSEcCtD
Vandetanib—FMO3—lymph node—germ cell cancer	8.31e-05	0.00103	CbGeAlD
Vandetanib—FYN—brain—germ cell cancer	8.3e-05	0.00102	CbGeAlD
Vandetanib—Gastrointestinal disorder—Cisplatin—germ cell cancer	8.3e-05	0.00126	CcSEcCtD
Vandetanib—Vomiting—Bleomycin—germ cell cancer	8.29e-05	0.00126	CcSEcCtD
Vandetanib—Infestation—Methotrexate—germ cell cancer	8.27e-05	0.00125	CcSEcCtD
Vandetanib—Infestation NOS—Methotrexate—germ cell cancer	8.27e-05	0.00125	CcSEcCtD
Vandetanib—SLK—lymph node—germ cell cancer	8.24e-05	0.00102	CbGeAlD
Vandetanib—Depression—Methotrexate—germ cell cancer	8.24e-05	0.00125	CcSEcCtD
Vandetanib—ABL1—adrenal gland—germ cell cancer	8.24e-05	0.00102	CbGeAlD
Vandetanib—Rash—Bleomycin—germ cell cancer	8.22e-05	0.00124	CcSEcCtD
Vandetanib—Pain—Cisplatin—germ cell cancer	8.22e-05	0.00124	CcSEcCtD
Vandetanib—Dermatitis—Bleomycin—germ cell cancer	8.22e-05	0.00124	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Methotrexate—germ cell cancer	8.2e-05	0.00124	CcSEcCtD
Vandetanib—ABCC1—decidua—germ cell cancer	8.18e-05	0.00101	CbGeAlD
Vandetanib—MAP2K5—cerebellum—germ cell cancer	8.16e-05	0.00101	CbGeAlD
Vandetanib—KDR—cerebellum—germ cell cancer	8.16e-05	0.00101	CbGeAlD
Vandetanib—ABL1—midbrain—germ cell cancer	8.14e-05	0.001	CbGeAlD
Vandetanib—Renal failure—Methotrexate—germ cell cancer	8.13e-05	0.00123	CcSEcCtD
Vandetanib—TEK—brain—germ cell cancer	8.11e-05	0.001	CbGeAlD
Vandetanib—MAP4K5—brain—germ cell cancer	8.11e-05	0.001	CbGeAlD
Vandetanib—Stomatitis—Methotrexate—germ cell cancer	8.06e-05	0.00122	CcSEcCtD
Vandetanib—Conjunctivitis—Methotrexate—germ cell cancer	8.04e-05	0.00122	CcSEcCtD
Vandetanib—PDGFRB—endocrine gland—germ cell cancer	8.02e-05	0.00099	CbGeAlD
Vandetanib—FYN—lymph node—germ cell cancer	8.02e-05	0.00099	CbGeAlD
Vandetanib—Asthenia—Ifosfamide—germ cell cancer	8e-05	0.00121	CcSEcCtD
Vandetanib—ABL1—bone marrow—germ cell cancer	7.97e-05	0.000985	CbGeAlD
Vandetanib—ABL1—spinal cord—germ cell cancer	7.94e-05	0.00098	CbGeAlD
Vandetanib—PDGFRB—head—germ cell cancer	7.91e-05	0.000978	CbGeAlD
Vandetanib—Paraesthesia—Etoposide—germ cell cancer	7.9e-05	0.0012	CcSEcCtD
Vandetanib—Pruritus—Ifosfamide—germ cell cancer	7.89e-05	0.00119	CcSEcCtD
Vandetanib—Haematuria—Methotrexate—germ cell cancer	7.88e-05	0.00119	CcSEcCtD
Vandetanib—Dyspnoea—Etoposide—germ cell cancer	7.85e-05	0.00119	CcSEcCtD
Vandetanib—MAP4K5—lymph node—germ cell cancer	7.83e-05	0.000968	CbGeAlD
Vandetanib—TEK—lymph node—germ cell cancer	7.83e-05	0.000968	CbGeAlD
Vandetanib—Hepatobiliary disease—Methotrexate—germ cell cancer	7.82e-05	0.00118	CcSEcCtD
Vandetanib—Epistaxis—Methotrexate—germ cell cancer	7.8e-05	0.00118	CcSEcCtD
Vandetanib—EPHB6—brain—germ cell cancer	7.75e-05	0.000957	CbGeAlD
Vandetanib—Nausea—Bleomycin—germ cell cancer	7.75e-05	0.00117	CcSEcCtD
Vandetanib—Vomiting—Dactinomycin—germ cell cancer	7.73e-05	0.00117	CcSEcCtD
Vandetanib—ABL1—female gonad—germ cell cancer	7.68e-05	0.000949	CbGeAlD
Vandetanib—Rash—Dactinomycin—germ cell cancer	7.67e-05	0.00116	CcSEcCtD
Vandetanib—Decreased appetite—Etoposide—germ cell cancer	7.65e-05	0.00116	CcSEcCtD
Vandetanib—PDGFRB—testis—germ cell cancer	7.65e-05	0.000944	CbGeAlD
Vandetanib—Diarrhoea—Ifosfamide—germ cell cancer	7.63e-05	0.00115	CcSEcCtD
Vandetanib—ALB—adrenal gland—germ cell cancer	7.6e-05	0.000939	CbGeAlD
Vandetanib—Gastrointestinal disorder—Etoposide—germ cell cancer	7.6e-05	0.00115	CcSEcCtD
Vandetanib—Body temperature increased—Cisplatin—germ cell cancer	7.6e-05	0.00115	CcSEcCtD
Vandetanib—Fatigue—Etoposide—germ cell cancer	7.59e-05	0.00115	CcSEcCtD
Vandetanib—Constipation—Etoposide—germ cell cancer	7.53e-05	0.00114	CcSEcCtD
Vandetanib—Pain—Etoposide—germ cell cancer	7.53e-05	0.00114	CcSEcCtD
Vandetanib—ORM1—endocrine gland—germ cell cancer	7.52e-05	0.000929	CbGeAlD
Vandetanib—YES1—brain—germ cell cancer	7.49e-05	0.000925	CbGeAlD
Vandetanib—EPHB6—lymph node—germ cell cancer	7.49e-05	0.000925	CbGeAlD
Vandetanib—Haemoglobin—Methotrexate—germ cell cancer	7.46e-05	0.00113	CcSEcCtD
Vandetanib—Haemorrhage—Methotrexate—germ cell cancer	7.42e-05	0.00112	CcSEcCtD
Vandetanib—STK10—brain—germ cell cancer	7.42e-05	0.000917	CbGeAlD
Vandetanib—Dizziness—Ifosfamide—germ cell cancer	7.37e-05	0.00112	CcSEcCtD
Vandetanib—Urinary tract disorder—Methotrexate—germ cell cancer	7.33e-05	0.00111	CcSEcCtD
Vandetanib—Urethral disorder—Methotrexate—germ cell cancer	7.28e-05	0.0011	CcSEcCtD
Vandetanib—YES1—lymph node—germ cell cancer	7.23e-05	0.000894	CbGeAlD
Vandetanib—Nausea—Dactinomycin—germ cell cancer	7.22e-05	0.00109	CcSEcCtD
Vandetanib—SRC—brain—germ cell cancer	7.2e-05	0.00089	CbGeAlD
Vandetanib—Gastrointestinal pain—Etoposide—germ cell cancer	7.2e-05	0.00109	CcSEcCtD
Vandetanib—STK10—lymph node—germ cell cancer	7.17e-05	0.000886	CbGeAlD
Vandetanib—ABCC1—uterus—germ cell cancer	7.15e-05	0.000884	CbGeAlD
Vandetanib—Visual impairment—Methotrexate—germ cell cancer	7.15e-05	0.00108	CcSEcCtD
Vandetanib—ABL1—endocrine gland—germ cell cancer	7.15e-05	0.000883	CbGeAlD
Vandetanib—ABCG2—telencephalon—germ cell cancer	7.14e-05	0.000882	CbGeAlD
Vandetanib—Vomiting—Ifosfamide—germ cell cancer	7.09e-05	0.00107	CcSEcCtD
Vandetanib—PDGFRB—cerebellum—germ cell cancer	7.06e-05	0.000872	CbGeAlD
Vandetanib—ABL1—head—germ cell cancer	7.05e-05	0.000871	CbGeAlD
Vandetanib—Rash—Ifosfamide—germ cell cancer	7.03e-05	0.00106	CcSEcCtD
Vandetanib—ABCC1—pituitary gland—germ cell cancer	7.03e-05	0.000868	CbGeAlD
Vandetanib—Dermatitis—Ifosfamide—germ cell cancer	7.02e-05	0.00106	CcSEcCtD
Vandetanib—Erythema multiforme—Methotrexate—germ cell cancer	7.02e-05	0.00106	CcSEcCtD
Vandetanib—SRC—lymph node—germ cell cancer	6.96e-05	0.00086	CbGeAlD
Vandetanib—Abdominal pain—Etoposide—germ cell cancer	6.96e-05	0.00105	CcSEcCtD
Vandetanib—Body temperature increased—Etoposide—germ cell cancer	6.96e-05	0.00105	CcSEcCtD
Vandetanib—Eye disorder—Methotrexate—germ cell cancer	6.94e-05	0.00105	CcSEcCtD
Vandetanib—Asthenia—Cisplatin—germ cell cancer	6.89e-05	0.00104	CcSEcCtD
Vandetanib—Cardiac disorder—Methotrexate—germ cell cancer	6.89e-05	0.00104	CcSEcCtD
Vandetanib—ABL1—testis—germ cell cancer	6.81e-05	0.000842	CbGeAlD
Vandetanib—ABCG2—decidua—germ cell cancer	6.77e-05	0.000836	CbGeAlD
Vandetanib—Angiopathy—Methotrexate—germ cell cancer	6.73e-05	0.00102	CcSEcCtD
Vandetanib—Mediastinal disorder—Methotrexate—germ cell cancer	6.69e-05	0.00101	CcSEcCtD
Vandetanib—MAP2K5—brain—germ cell cancer	6.63e-05	0.000819	CbGeAlD
Vandetanib—KDR—brain—germ cell cancer	6.63e-05	0.000819	CbGeAlD
Vandetanib—Nausea—Ifosfamide—germ cell cancer	6.62e-05	0.001	CcSEcCtD
Vandetanib—Diarrhoea—Cisplatin—germ cell cancer	6.57e-05	0.000995	CcSEcCtD
Vandetanib—Alopecia—Methotrexate—germ cell cancer	6.56e-05	0.000993	CcSEcCtD
Vandetanib—Mental disorder—Methotrexate—germ cell cancer	6.5e-05	0.000984	CcSEcCtD
Vandetanib—Malnutrition—Methotrexate—germ cell cancer	6.46e-05	0.000978	CcSEcCtD
Vandetanib—KDR—lymph node—germ cell cancer	6.4e-05	0.000791	CbGeAlD
Vandetanib—MAP2K5—lymph node—germ cell cancer	6.4e-05	0.000791	CbGeAlD
Vandetanib—Dysgeusia—Methotrexate—germ cell cancer	6.33e-05	0.000958	CcSEcCtD
Vandetanib—Asthenia—Etoposide—germ cell cancer	6.32e-05	0.000956	CcSEcCtD
Vandetanib—ABL1—cerebellum—germ cell cancer	6.29e-05	0.000777	CbGeAlD
Vandetanib—ALB—testis—germ cell cancer	6.29e-05	0.000777	CbGeAlD
Vandetanib—ABCC1—adrenal gland—germ cell cancer	6.28e-05	0.000775	CbGeAlD
Vandetanib—Pruritus—Etoposide—germ cell cancer	6.23e-05	0.000943	CcSEcCtD
Vandetanib—Vomiting—Cisplatin—germ cell cancer	6.11e-05	0.000925	CcSEcCtD
Vandetanib—Vision blurred—Methotrexate—germ cell cancer	6.09e-05	0.000922	CcSEcCtD
Vandetanib—Rash—Cisplatin—germ cell cancer	6.06e-05	0.000917	CcSEcCtD
Vandetanib—Dermatitis—Cisplatin—germ cell cancer	6.05e-05	0.000916	CcSEcCtD
Vandetanib—Diarrhoea—Etoposide—germ cell cancer	6.02e-05	0.000912	CcSEcCtD
Vandetanib—ABCG2—uterus—germ cell cancer	5.92e-05	0.000732	CbGeAlD
Vandetanib—ABCC1—female gonad—germ cell cancer	5.85e-05	0.000723	CbGeAlD
Vandetanib—Dizziness—Etoposide—germ cell cancer	5.82e-05	0.000881	CcSEcCtD
Vandetanib—ABCG2—pituitary gland—germ cell cancer	5.82e-05	0.000718	CbGeAlD
Vandetanib—PDGFRB—brain—germ cell cancer	5.74e-05	0.000708	CbGeAlD
Vandetanib—Nausea—Cisplatin—germ cell cancer	5.71e-05	0.000864	CcSEcCtD
Vandetanib—Cough—Methotrexate—germ cell cancer	5.64e-05	0.000853	CcSEcCtD
Vandetanib—ABCG2—medulla oblongata—germ cell cancer	5.61e-05	0.000693	CbGeAlD
Vandetanib—Convulsion—Methotrexate—germ cell cancer	5.6e-05	0.000847	CcSEcCtD
Vandetanib—Vomiting—Etoposide—germ cell cancer	5.6e-05	0.000847	CcSEcCtD
Vandetanib—Rash—Etoposide—germ cell cancer	5.55e-05	0.00084	CcSEcCtD
Vandetanib—Dermatitis—Etoposide—germ cell cancer	5.55e-05	0.000839	CcSEcCtD
Vandetanib—PDGFRB—lymph node—germ cell cancer	5.54e-05	0.000685	CbGeAlD
Vandetanib—Headache—Etoposide—germ cell cancer	5.51e-05	0.000835	CcSEcCtD
Vandetanib—Arthralgia—Methotrexate—germ cell cancer	5.5e-05	0.000833	CcSEcCtD
Vandetanib—Chest pain—Methotrexate—germ cell cancer	5.5e-05	0.000833	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—germ cell cancer	5.46e-05	0.000827	CcSEcCtD
Vandetanib—Infection—Methotrexate—germ cell cancer	5.24e-05	0.000793	CcSEcCtD
Vandetanib—Nausea—Etoposide—germ cell cancer	5.23e-05	0.000792	CcSEcCtD
Vandetanib—ORM1—lymph node—germ cell cancer	5.2e-05	0.000642	CbGeAlD
Vandetanib—ABCG2—adrenal gland—germ cell cancer	5.2e-05	0.000642	CbGeAlD
Vandetanib—ABCC1—testis—germ cell cancer	5.19e-05	0.000641	CbGeAlD
Vandetanib—Nervous system disorder—Methotrexate—germ cell cancer	5.17e-05	0.000783	CcSEcCtD
Vandetanib—Thrombocytopenia—Methotrexate—germ cell cancer	5.16e-05	0.000782	CcSEcCtD
Vandetanib—ABCG2—midbrain—germ cell cancer	5.13e-05	0.000634	CbGeAlD
Vandetanib—Skin disorder—Methotrexate—germ cell cancer	5.12e-05	0.000775	CcSEcCtD
Vandetanib—ABL1—brain—germ cell cancer	5.11e-05	0.000631	CbGeAlD
Vandetanib—ABCG2—bone marrow—germ cell cancer	5.03e-05	0.000621	CbGeAlD
Vandetanib—ABCG2—spinal cord—germ cell cancer	5.01e-05	0.000618	CbGeAlD
Vandetanib—ABL1—lymph node—germ cell cancer	4.94e-05	0.00061	CbGeAlD
Vandetanib—ABCG2—female gonad—germ cell cancer	4.84e-05	0.000598	CbGeAlD
Vandetanib—Musculoskeletal discomfort—Methotrexate—germ cell cancer	4.8e-05	0.000727	CcSEcCtD
Vandetanib—ABCC1—cerebellum—germ cell cancer	4.79e-05	0.000592	CbGeAlD
Vandetanib—Insomnia—Methotrexate—germ cell cancer	4.77e-05	0.000722	CcSEcCtD
Vandetanib—Paraesthesia—Methotrexate—germ cell cancer	4.73e-05	0.000717	CcSEcCtD
Vandetanib—ALB—brain—germ cell cancer	4.72e-05	0.000583	CbGeAlD
Vandetanib—Dyspnoea—Methotrexate—germ cell cancer	4.7e-05	0.000712	CcSEcCtD
Vandetanib—Dyspepsia—Methotrexate—germ cell cancer	4.64e-05	0.000703	CcSEcCtD
Vandetanib—Decreased appetite—Methotrexate—germ cell cancer	4.58e-05	0.000694	CcSEcCtD
Vandetanib—ALB—lymph node—germ cell cancer	4.56e-05	0.000563	CbGeAlD
Vandetanib—Gastrointestinal disorder—Methotrexate—germ cell cancer	4.55e-05	0.000689	CcSEcCtD
Vandetanib—Fatigue—Methotrexate—germ cell cancer	4.55e-05	0.000688	CcSEcCtD
Vandetanib—Pain—Methotrexate—germ cell cancer	4.51e-05	0.000683	CcSEcCtD
Vandetanib—Gastrointestinal pain—Methotrexate—germ cell cancer	4.31e-05	0.000653	CcSEcCtD
Vandetanib—ABCG2—testis—germ cell cancer	4.3e-05	0.000531	CbGeAlD
Vandetanib—Abdominal pain—Methotrexate—germ cell cancer	4.17e-05	0.000631	CcSEcCtD
Vandetanib—Body temperature increased—Methotrexate—germ cell cancer	4.17e-05	0.000631	CcSEcCtD
Vandetanib—ABCG2—cerebellum—germ cell cancer	3.97e-05	0.00049	CbGeAlD
Vandetanib—ABCC1—brain—germ cell cancer	3.89e-05	0.000481	CbGeAlD
Vandetanib—Asthenia—Methotrexate—germ cell cancer	3.78e-05	0.000573	CcSEcCtD
Vandetanib—ABCC1—lymph node—germ cell cancer	3.76e-05	0.000465	CbGeAlD
Vandetanib—Pruritus—Methotrexate—germ cell cancer	3.73e-05	0.000565	CcSEcCtD
Vandetanib—Diarrhoea—Methotrexate—germ cell cancer	3.61e-05	0.000546	CcSEcCtD
Vandetanib—Dizziness—Methotrexate—germ cell cancer	3.49e-05	0.000528	CcSEcCtD
Vandetanib—Vomiting—Methotrexate—germ cell cancer	3.35e-05	0.000508	CcSEcCtD
Vandetanib—Rash—Methotrexate—germ cell cancer	3.32e-05	0.000503	CcSEcCtD
Vandetanib—Dermatitis—Methotrexate—germ cell cancer	3.32e-05	0.000503	CcSEcCtD
Vandetanib—Headache—Methotrexate—germ cell cancer	3.3e-05	0.0005	CcSEcCtD
Vandetanib—ABCG2—brain—germ cell cancer	3.22e-05	0.000398	CbGeAlD
Vandetanib—CYP3A4—endocrine gland—germ cell cancer	3.14e-05	0.000388	CbGeAlD
Vandetanib—Nausea—Methotrexate—germ cell cancer	3.13e-05	0.000474	CcSEcCtD
Vandetanib—ABCG2—lymph node—germ cell cancer	3.11e-05	0.000385	CbGeAlD
Vandetanib—SRC—Signaling by PDGF—HRAS—germ cell cancer	8.06e-06	0.000103	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—KIT—germ cell cancer	8.04e-06	0.000102	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—OXT—germ cell cancer	8.04e-06	0.000102	CbGpPWpGaD
Vandetanib—LCK—Disease—FGF4—germ cell cancer	8.03e-06	0.000102	CbGpPWpGaD
Vandetanib—YES1—Immune System—KIT—germ cell cancer	7.98e-06	0.000102	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—AVP—germ cell cancer	7.93e-06	0.000101	CbGpPWpGaD
Vandetanib—FYN—Disease—KITLG—germ cell cancer	7.93e-06	0.000101	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—OXT—germ cell cancer	7.91e-06	0.000101	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling by NGF—HRAS—germ cell cancer	7.91e-06	0.000101	CbGpPWpGaD
Vandetanib—ABCC1—Disease—H2AFZ—germ cell cancer	7.9e-06	0.000101	CbGpPWpGaD
Vandetanib—AXL—Signaling Pathways—MYC—germ cell cancer	7.87e-06	0.0001	CbGpPWpGaD
Vandetanib—LYN—Cytokine Signaling in Immune system—HRAS—germ cell cancer	7.87e-06	0.0001	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—KITLG—germ cell cancer	7.83e-06	9.97e-05	CbGpPWpGaD
Vandetanib—MKNK1—Disease—MYC—germ cell cancer	7.79e-06	9.93e-05	CbGpPWpGaD
Vandetanib—SRC—Focal Adhesion—HRAS—germ cell cancer	7.79e-06	9.92e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—FGFR3—germ cell cancer	7.75e-06	9.88e-05	CbGpPWpGaD
Vandetanib—FYN—Cytokine Signaling in Immune system—HRAS—germ cell cancer	7.75e-06	9.87e-05	CbGpPWpGaD
Vandetanib—KDR—Developmental Biology—HRAS—germ cell cancer	7.72e-06	9.84e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—FGF4—germ cell cancer	7.7e-06	9.81e-05	CbGpPWpGaD
Vandetanib—RIPK2—Innate Immune System—HRAS—germ cell cancer	7.65e-06	9.75e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—AVP—germ cell cancer	7.65e-06	9.75e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling by NGF—HRAS—germ cell cancer	7.62e-06	9.71e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—KITLG—germ cell cancer	7.56e-06	9.63e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—H2AFZ—germ cell cancer	7.44e-06	9.48e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—KITLG—germ cell cancer	7.42e-06	9.45e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—KIT—germ cell cancer	7.41e-06	9.44e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—AVP—germ cell cancer	7.39e-06	9.41e-05	CbGpPWpGaD
Vandetanib—RIPK2—Adaptive Immune System—HRAS—germ cell cancer	7.35e-06	9.36e-05	CbGpPWpGaD
Vandetanib—FGR—Innate Immune System—HRAS—germ cell cancer	7.33e-06	9.34e-05	CbGpPWpGaD
Vandetanib—SRC—NGF signalling via TRKA from the plasma membrane—HRAS—germ cell cancer	7.3e-06	9.3e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—KITLG—germ cell cancer	7.26e-06	9.25e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—FGFR3—germ cell cancer	7.26e-06	9.25e-05	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—MYC—germ cell cancer	7.2e-06	9.17e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—H2AFZ—germ cell cancer	7.17e-06	9.14e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—KITLG—germ cell cancer	7.15e-06	9.1e-05	CbGpPWpGaD
Vandetanib—VEGFA—Hemostasis—TP53—germ cell cancer	7.12e-06	9.07e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—KIT—germ cell cancer	7.12e-06	9.07e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—FGF4—germ cell cancer	7.11e-06	9.06e-05	CbGpPWpGaD
Vandetanib—BLK—Adaptive Immune System—HRAS—germ cell cancer	7.07e-06	9e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—FGF4—germ cell cancer	7.01e-06	8.93e-05	CbGpPWpGaD
Vandetanib—LYN—Axon guidance—HRAS—germ cell cancer	7e-06	8.92e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—SLC2A3—germ cell cancer	7e-06	8.92e-05	CbGpPWpGaD
Vandetanib—ABL1—Axon guidance—HRAS—germ cell cancer	6.97e-06	8.88e-05	CbGpPWpGaD
Vandetanib—VEGFA—Developmental Biology—HRAS—germ cell cancer	6.94e-06	8.84e-05	CbGpPWpGaD
Vandetanib—FYN—Axon guidance—HRAS—germ cell cancer	6.9e-06	8.79e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—SLC22A3—germ cell cancer	6.9e-06	8.78e-05	CbGpPWpGaD
Vandetanib—ALB—Transmembrane transport of small molecules—AVP—germ cell cancer	6.89e-06	8.78e-05	CbGpPWpGaD
Vandetanib—YES1—Hemostasis—TP53—germ cell cancer	6.88e-06	8.76e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—FGF4—germ cell cancer	6.86e-06	8.74e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—KITLG—germ cell cancer	6.85e-06	8.72e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—OXT—germ cell cancer	6.84e-06	8.71e-05	CbGpPWpGaD
Vandetanib—VEGFA—Hemostasis—HRAS—germ cell cancer	6.81e-06	8.67e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—FGF4—germ cell cancer	6.76e-06	8.61e-05	CbGpPWpGaD
Vandetanib—ERBB3—Innate Immune System—HRAS—germ cell cancer	6.74e-06	8.59e-05	CbGpPWpGaD
Vandetanib—YES1—Developmental Biology—HRAS—germ cell cancer	6.7e-06	8.54e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—KIT—germ cell cancer	6.67e-06	8.49e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—FGFR3—germ cell cancer	6.64e-06	8.46e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—FGFR3—germ cell cancer	6.62e-06	8.43e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—KITLG—germ cell cancer	6.6e-06	8.41e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—OXT—germ cell cancer	6.59e-06	8.39e-05	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—MYC—germ cell cancer	6.59e-06	8.39e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by NGF—HRAS—germ cell cancer	6.58e-06	8.39e-05	CbGpPWpGaD
Vandetanib—YES1—Hemostasis—HRAS—germ cell cancer	6.58e-06	8.38e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—FGFR3—germ cell cancer	6.48e-06	8.26e-05	CbGpPWpGaD
Vandetanib—ERBB3—Adaptive Immune System—HRAS—germ cell cancer	6.48e-06	8.25e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—FGFR3—germ cell cancer	6.47e-06	8.24e-05	CbGpPWpGaD
Vandetanib—AXL—Signaling Pathways—TP53—germ cell cancer	6.47e-06	8.24e-05	CbGpPWpGaD
Vandetanib—LCK—Cytokine Signaling in Immune system—HRAS—germ cell cancer	6.45e-06	8.22e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—FGFR3—germ cell cancer	6.45e-06	8.22e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—FGFR3—germ cell cancer	6.4e-06	8.15e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—FGFR3—germ cell cancer	6.38e-06	8.13e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—H2AFZ—germ cell cancer	6.35e-06	8.09e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling by NGF—HRAS—germ cell cancer	6.34e-06	8.08e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—KITLG—germ cell cancer	6.33e-06	8.06e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—H2AFZ—germ cell cancer	6.26e-06	7.97e-05	CbGpPWpGaD
Vandetanib—AXL—Signaling Pathways—HRAS—germ cell cancer	6.18e-06	7.88e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—H2AFZ—germ cell cancer	6.13e-06	7.81e-05	CbGpPWpGaD
Vandetanib—MKNK1—Disease—HRAS—germ cell cancer	6.12e-06	7.8e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—FGFR3—germ cell cancer	6.11e-06	7.79e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—KIT—germ cell cancer	6.1e-06	7.77e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—KIT—germ cell cancer	6.08e-06	7.74e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—H2AFZ—germ cell cancer	6.03e-06	7.69e-05	CbGpPWpGaD
Vandetanib—EGFR—Axon guidance—HRAS—germ cell cancer	5.96e-06	7.59e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—KIT—germ cell cancer	5.95e-06	7.58e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—KIT—germ cell cancer	5.94e-06	7.57e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—KIT—germ cell cancer	5.92e-06	7.54e-05	CbGpPWpGaD
Vandetanib—YES1—Innate Immune System—HRAS—germ cell cancer	5.92e-06	7.54e-05	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—TP53—germ cell cancer	5.91e-06	7.53e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—FGFR3—germ cell cancer	5.89e-06	7.5e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—KIT—germ cell cancer	5.88e-06	7.49e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—KIT—germ cell cancer	5.86e-06	7.46e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—KITLG—germ cell cancer	5.84e-06	7.44e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—FGF4—germ cell cancer	5.84e-06	7.44e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—OXT—germ cell cancer	5.83e-06	7.43e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—FGFR3—germ cell cancer	5.82e-06	7.41e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—KITLG—germ cell cancer	5.76e-06	7.34e-05	CbGpPWpGaD
Vandetanib—YES1—Adaptive Immune System—HRAS—germ cell cancer	5.69e-06	7.24e-05	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—HRAS—germ cell cancer	5.66e-06	7.21e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—KITLG—germ cell cancer	5.64e-06	7.18e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—AVP—germ cell cancer	5.63e-06	7.17e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—FGF4—germ cell cancer	5.62e-06	7.17e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—CRABP1—germ cell cancer	5.62e-06	7.16e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—FGFR3—germ cell cancer	5.62e-06	7.16e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling by NGF—HRAS—germ cell cancer	5.62e-06	7.15e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—KIT—germ cell cancer	5.61e-06	7.15e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—KITLG—germ cell cancer	5.55e-06	7.07e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—FGFR3—germ cell cancer	5.51e-06	7.02e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—AVP—germ cell cancer	5.51e-06	7.02e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—MYC—germ cell cancer	5.46e-06	6.95e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—AVP—germ cell cancer	5.42e-06	6.91e-05	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—TP53—germ cell cancer	5.41e-06	6.89e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—KIT—germ cell cancer	5.41e-06	6.89e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—FGFR3—germ cell cancer	5.4e-06	6.88e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—KIT—germ cell cancer	5.34e-06	6.8e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—FGFR3—germ cell cancer	5.31e-06	6.77e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—H2AFZ—germ cell cancer	5.21e-06	6.64e-05	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—HRAS—germ cell cancer	5.17e-06	6.59e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—KIT—germ cell cancer	5.16e-06	6.57e-05	CbGpPWpGaD
Vandetanib—LYN—Hemostasis—TP53—germ cell cancer	5.13e-06	6.53e-05	CbGpPWpGaD
Vandetanib—ABL1—Hemostasis—TP53—germ cell cancer	5.1e-06	6.5e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—FGFR3—germ cell cancer	5.09e-06	6.48e-05	CbGpPWpGaD
Vandetanib—SRC—Axon guidance—HRAS—germ cell cancer	5.08e-06	6.48e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—KIT—germ cell cancer	5.06e-06	6.45e-05	CbGpPWpGaD
Vandetanib—FYN—Hemostasis—TP53—germ cell cancer	5.05e-06	6.43e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—H2AFZ—germ cell cancer	5.02e-06	6.4e-05	CbGpPWpGaD
Vandetanib—LYN—Developmental Biology—HRAS—germ cell cancer	5e-06	6.37e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—FGF4—germ cell cancer	4.98e-06	6.34e-05	CbGpPWpGaD
Vandetanib—ABL1—Developmental Biology—HRAS—germ cell cancer	4.98e-06	6.34e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—KIT—germ cell cancer	4.96e-06	6.31e-05	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—HRAS—germ cell cancer	4.93e-06	6.28e-05	CbGpPWpGaD
Vandetanib—FYN—Developmental Biology—HRAS—germ cell cancer	4.92e-06	6.27e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—FGFR3—germ cell cancer	4.9e-06	6.25e-05	CbGpPWpGaD
Vandetanib—LYN—Hemostasis—HRAS—germ cell cancer	4.9e-06	6.25e-05	CbGpPWpGaD
Vandetanib—ABL1—Hemostasis—HRAS—germ cell cancer	4.88e-06	6.22e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—KIT—germ cell cancer	4.88e-06	6.21e-05	CbGpPWpGaD
Vandetanib—FYN—Hemostasis—HRAS—germ cell cancer	4.83e-06	6.15e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—KITLG—germ cell cancer	4.79e-06	6.11e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—FGFR3—germ cell cancer	4.7e-06	5.99e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—AVP—germ cell cancer	4.69e-06	5.97e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—KIT—germ cell cancer	4.67e-06	5.95e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—KITLG—germ cell cancer	4.62e-06	5.89e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—MYC—germ cell cancer	4.62e-06	5.88e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—AVP—germ cell cancer	4.52e-06	5.75e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—HRAS—germ cell cancer	4.51e-06	5.74e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—KIT—germ cell cancer	4.5e-06	5.74e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—TP53—germ cell cancer	4.48e-06	5.71e-05	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—HRAS—germ cell cancer	4.46e-06	5.68e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—H2AFZ—germ cell cancer	4.45e-06	5.66e-05	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—HRAS—germ cell cancer	4.41e-06	5.62e-05	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—HRAS—germ cell cancer	4.39e-06	5.6e-05	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—HRAS—germ cell cancer	4.35e-06	5.54e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—FGFR3—germ cell cancer	4.34e-06	5.53e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Adaptive Immune System—HRAS—germ cell cancer	4.33e-06	5.52e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—KIT—germ cell cancer	4.32e-06	5.5e-05	CbGpPWpGaD
Vandetanib—BLK—Immune System—HRAS—germ cell cancer	4.29e-06	5.46e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—HRAS—germ cell cancer	4.29e-06	5.46e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—FGFR3—germ cell cancer	4.28e-06	5.45e-05	CbGpPWpGaD
Vandetanib—FGR—Immune System—HRAS—germ cell cancer	4.27e-06	5.44e-05	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—HRAS—germ cell cancer	4.25e-06	5.42e-05	CbGpPWpGaD
Vandetanib—LYN—Adaptive Immune System—HRAS—germ cell cancer	4.24e-06	5.4e-05	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—TP53—germ cell cancer	4.2e-06	5.35e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—FGFR3—germ cell cancer	4.19e-06	5.34e-05	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—HRAS—germ cell cancer	4.17e-06	5.32e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—FGFR3—germ cell cancer	4.12e-06	5.25e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—KITLG—germ cell cancer	4.09e-06	5.21e-05	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—HRAS—germ cell cancer	4.02e-06	5.12e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—AVP—germ cell cancer	4e-06	5.09e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—KIT—germ cell cancer	3.99e-06	5.08e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—KIT—germ cell cancer	3.93e-06	5.01e-05	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—HRAS—germ cell cancer	3.93e-06	5e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—KIT—germ cell cancer	3.85e-06	4.9e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—KIT—germ cell cancer	3.79e-06	4.82e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—SLC2A3—germ cell cancer	3.78e-06	4.81e-05	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—HRAS—germ cell cancer	3.75e-06	4.78e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—SLC22A3—germ cell cancer	3.72e-06	4.74e-05	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—TP53—germ cell cancer	3.72e-06	4.74e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—MYC—germ cell cancer	3.67e-06	4.67e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—HRAS—germ cell cancer	3.63e-06	4.62e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—HRAS—germ cell cancer	3.63e-06	4.62e-05	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—HRAS—germ cell cancer	3.62e-06	4.61e-05	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—HRAS—germ cell cancer	3.61e-06	4.59e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—FGFR3—germ cell cancer	3.56e-06	4.54e-05	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—HRAS—germ cell cancer	3.56e-06	4.53e-05	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—HRAS—germ cell cancer	3.47e-06	4.43e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—HRAS—germ cell cancer	3.45e-06	4.39e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—FGFR3—germ cell cancer	3.43e-06	4.37e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—MYC—germ cell cancer	3.35e-06	4.27e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—KIT—germ cell cancer	3.27e-06	4.17e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—MYC—germ cell cancer	3.27e-06	4.17e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—MYC—germ cell cancer	3.23e-06	4.12e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—HRAS—germ cell cancer	3.2e-06	4.08e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—KIT—germ cell cancer	3.15e-06	4.02e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—MYC—germ cell cancer	3.09e-06	3.93e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—HRAS—germ cell cancer	3.08e-06	3.92e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—FGFR3—germ cell cancer	3.04e-06	3.87e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CRABP1—germ cell cancer	3.03e-06	3.87e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—TP53—germ cell cancer	3.01e-06	3.84e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—MYC—germ cell cancer	2.98e-06	3.79e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—MYC—germ cell cancer	2.94e-06	3.74e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—HRAS—germ cell cancer	2.88e-06	3.67e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—MYC—germ cell cancer	2.84e-06	3.62e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—KIT—germ cell cancer	2.79e-06	3.56e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—TP53—germ cell cancer	2.76e-06	3.51e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—MYC—germ cell cancer	2.73e-06	3.47e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—TP53—germ cell cancer	2.68e-06	3.42e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—TP53—germ cell cancer	2.66e-06	3.38e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—HRAS—germ cell cancer	2.63e-06	3.36e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—HRAS—germ cell cancer	2.63e-06	3.35e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—HRAS—germ cell cancer	2.57e-06	3.28e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—MYC—germ cell cancer	2.57e-06	3.28e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—HRAS—germ cell cancer	2.57e-06	3.27e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—HRAS—germ cell cancer	2.56e-06	3.26e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—HRAS—germ cell cancer	2.54e-06	3.24e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—HRAS—germ cell cancer	2.53e-06	3.22e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—TP53—germ cell cancer	2.51e-06	3.2e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—MYC—germ cell cancer	2.48e-06	3.16e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—HRAS—germ cell cancer	2.42e-06	3.09e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TP53—germ cell cancer	2.41e-06	3.07e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—HRAS—germ cell cancer	2.4e-06	3.06e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—HRAS—germ cell cancer	2.39e-06	3.05e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—HRAS—germ cell cancer	2.34e-06	2.98e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TP53—germ cell cancer	2.33e-06	2.97e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—HRAS—germ cell cancer	2.31e-06	2.94e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—HRAS—germ cell cancer	2.23e-06	2.84e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—MYC—germ cell cancer	2.19e-06	2.79e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—HRAS—germ cell cancer	2.19e-06	2.79e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MYC—germ cell cancer	2.16e-06	2.75e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—HRAS—germ cell cancer	2.14e-06	2.73e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MYC—germ cell cancer	2.12e-06	2.7e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—HRAS—germ cell cancer	2.11e-06	2.68e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MYC—germ cell cancer	2.08e-06	2.65e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—HRAS—germ cell cancer	2.02e-06	2.57e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—HRAS—germ cell cancer	1.95e-06	2.48e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—HRAS—germ cell cancer	1.87e-06	2.38e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MYC—germ cell cancer	1.8e-06	2.29e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TP53—germ cell cancer	1.78e-06	2.26e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TP53—germ cell cancer	1.74e-06	2.21e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MYC—germ cell cancer	1.73e-06	2.21e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—HRAS—germ cell cancer	1.72e-06	2.19e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TP53—germ cell cancer	1.71e-06	2.18e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—HRAS—germ cell cancer	1.7e-06	2.16e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—HRAS—germ cell cancer	1.66e-06	2.12e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—HRAS—germ cell cancer	1.64e-06	2.08e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MYC—germ cell cancer	1.54e-06	1.96e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TP53—germ cell cancer	1.48e-06	1.88e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TP53—germ cell cancer	1.42e-06	1.82e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—HRAS—germ cell cancer	1.41e-06	1.8e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—HRAS—germ cell cancer	1.36e-06	1.74e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TP53—germ cell cancer	1.26e-06	1.61e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—HRAS—germ cell cancer	1.21e-06	1.54e-05	CbGpPWpGaD
